Anxiety Disorders: Current Needs and Future Prospects

Anxiety Disorders

Volumn , Issue , 2007, Pages 499-510

  Nutt, D ^a   Ballenger, J ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Anxiety disorders; Neurotransmitters; Norepinephrine depletion?; Weinstein Nutt; aminobutirric acid A (GABAA)

Indexed keywords

EID: 84951941361     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470986844.ch28     Document Type: Chapter

References (41)

1. Anderson, I. (2001) Meta-analytical studies on new antide-pressants. Br Med Bull, 57, 161-78.
2. Argyropoulos, S.V. & Nutt, D.J. (2000) Substance P antagonists: novel agents in the treatment of depression. Expert Opin Investig Drugs 9(8), 1871-5.
3. Ballenger, J.C. (1999) Current treatments of the anxiety disorders in adults. Biol Psychiatry 46(11), 1579-94.
4. Barr, L.C., Goodman, W.K., McDougle, C.J. et al. (1994) Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 51, 309-17.
5. Bell, C., Abrams, J. & Nutt, D.J. (2001) Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178, 399-405.
6. Bell, C., Forshall, S., Adrover, M. et al. (2002) Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 16(1), 5-14.
7. Bradwejn, J. & Koszycki, D. (1994) Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 151, 261-3.
8. Davidson, J.R., Tupler, L.A. & Potts, N.L. (1994) Treatment of social phobia with benzodiazepines. J Clin Psychiatry 55 (Suppl.), 28-32.
9. Deakin, J.F.W. & Graeff, F.G. (1991) 5-HT and mechanisms of defence. J Psychopharmacol 5(4), 305-15.
10. Delgado, P.L., Charney, D.S., Price, L.H., Aghajanian, G.K., Landis, H. & Heninger, G.R. (1990) Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47, 411-18.
11. Delgado, P.L., Miller, H.L., Salomon, R.M. et al. (1999) Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine. Implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46, 212-20.
12. Forshall, S., Bell, C. & Nutt, D.J. (2000) Relapse of panic symptoms after rapid depletion of tryptophan. J Psychopharmacol 14(3) (Suppl.), A30-33.
13. Gutman, D.A., Owens, M.J. & Nemeroff, C.B. (2001) CRF receptor antagonists: a new approach to the treatment of depression. Pharmaceutical News 8, 18-25.
14. Johansson, L., Sohn, D., Thorberg, S. et al. (1997) The pharmacological characterization of a novel selective 5-hydroxytryptamine 1A receptor antagonist. NAD-299 The J Pharmacol Exp Ther 283(1), 216-25.
15. Kramer, M.S., Cutler, N., Feighner, J. et al. (1998) Dis-tinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (5383), 1640-5.
16. Leonard, H.L., Swedo, S.E., Lenane, M.C. et al. (1991) A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 48(10), 922-27.
17. Levine, L.R. & Potter, W.Z. (2000) The 5-HT1A receptor: an unkept promise? In: Anxiolytics (M. Briley & D.J. Nutt (eds), pp. 95-104). Birkhauser Verlag, Switzerland.
18. Lingford-Hughes AR, Uh1 N, Feeney AJ, Wilson SJ, Grasby PG, D'Orlando K, Gammans R, Nutt DJ. (2000). Is pagoclone a partial agonist at the central GABA-benzodiazepine receptor: A [11C]-flumazenil positron emission tomography study? Int J Neuropsychopharm 3, S288.
19. Lotufo-Neto, F., Bernik, M., Ramos, R.T. et al. (2001) A dose-finding and discontinuation study of clomipramine in panic disorder. J Psychopharmacol 15, 13-17.
20. Marks, I.M. (2002) The maturing of therapy: Some brief psychotherapies help anxiety/depressive disorders but mechanisms of action are unclear. Br J Psychiatry 180, 200-4.
21. Mavissakalian, M. & Perel, I.M. (1988) Imipramine dose-response relationship in panic disorder with agoraphobia. Arch Gen Psychiatry 46, 127-31.
22. McKernan, R.M., Rosahl, T.W., Reynolds, D.S. et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAa receptor a1 subtype. Nat Neurosci 3, 587-92.
23. Melichar, J.K., Haida, A., Rhodes, C., Reynolds, A.H., Nutt, D.J. & Malizia, A.L. (2001) Venlafaxine occupation at the noradrenaline reuptake site: in vivo determination in healthy volunteers. J Psychopharmacol 15(1), 9-12.
24. Middleton, H.C. (1991) 5-HT and mechanisms of defence. J Psychopharmacol 5(4), 281-5.
25. Miller, H.L., Delgado, P.L., Salomon, R.M. et al. (1996) Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 53(2), 117-28.
26. Nutt, D.J. (1998a) Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. Depress Anxiety 7(1), 7-10.
27. Nutt, D.J. (1998b) Substance-P antagonists: a new treatment for depression? Lancet 352, 1644-6.
28. Nutt, D.J. (2000) The psychobiology of post-traumatic stress disorder. J Clin Psychiatry 61(5), 24-32.
29. Nutt, D.J. (2001) Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 62(11), 22-7.
30. Nutt, D.J. & Cowen, P.J. (1987) Diazepam alters brain 5-HT function in man. Implications for the acute and chronic effects of benzodiazepines. Psychol Med 17, 601-7.
31. Nutt, D.J. & Johnson, F.N. (1998) Potential applications of venlafaxine. Reviews in Contemporary Pharmacotherapy 9(5), 321-31.
32. Nutt, D.J. & Malizia, A.L. (2001) New insights into the role of the GABAA benzodiazepine receptor. Br J Psychiatry 179, 390-6.
33. O'Brien, M. & Nutt, D.J. (1998) Loss of consciousness and PTSD a clue to aetiology and treatment? Br J Psychiatry 173, 102-4.
34. Pike, V.W., McCarron, J.A., Lammertsma, A.A. et al. (1996) Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. Eur J Pharmacol 301, 1-3.
35. Sandford, J.J., Forshall, S., Bell, C., Argyropoulos, S., D'Orlando, K.J., Gammans, R.E. & Nutt, D.J. (2001) Crossover trial of partial agonist pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharm 15(3), 205-8.
36. Sargent, P.A., Nash, J., Hood, S. et al. (2000) 5-HT1A receptor binding in panic disorder; comparison with depressive disorder and healthy volunteers using PET and [11C]WAY-100635. Neuroimage, 11(5), 189.
37. Smeraldi, E., Diaferia, G., Erzegovesi, S., Lucca, A., Bellodi, L. & Moja, E.A. (1996) Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry 40, 398-402.
38. van Vliet, I.M., Westenberg, H.G. & den Boer, J.A. (1996) Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology (Berl) 127(2), 174-80.
39. Weinstein, A.M. & Nutt, D.J. (1995) A cognitive dysfunction in anxiety and its amelioration by effective treatment with SSRIs. J Psychopharm 9(2), 83-9.
40. Wilson, S.J., Birnie, A., Sheridan, B. & Nutt, D.J. (1997) Sleep effects of pagoclone, a new benzodiazepine partial agonist. British Sleep Society meeting.
41. Zobel, A.W. et al. (2001) Effects of the high affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34, 171-81.